Clinical trial · no report yet · Phase 1/Phase 2
NCT07150806
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
- NCT07150806 ↗
- Recruiting
- Joshua Palmer
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Progressive/Recurrent Intracranial Meningioma Treated With SSTR-Targeted Alpha Emitter RYZ101 (PRIMe-STAR)
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Recurrent Meningioma
- Interventions
- Actinium Ac 225 DOTATATE RYZ101; Biospecimen Collection; Computed Tomography; Echocardiography Test; Gallium Ga 68-DOTATATE; L-lysine/L-arginine-containing Amino Acid; Magnetic Resonance Imaging; Multigated Acquisition Scan; Positron Emission Tomography; Somatostatin Receptor Positron Emission Tomography
- Arms
- Treatment (RYZ101) · Experimental
- Enrollment
- 30 (estimated)
- Primary outcomes
- Progression free survival (PFS)
- Sponsor
- Joshua Palmer with RayzeBio, Inc.
- Start
- Nov 12, 2025
- Primary completion
- Dec 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT07150806 · updated Aug 13, 2026